• Article Graphic
  • Article Graphic
  • Article Graphic
  • Article Graphic

Who We Are

Leidos Logo

The Frederick National Laboratory for Cancer Research (FNLCR) is a major part of the only Federally Funded Research and Development Center (FFRDC) dedicated to biomedical research. FNLCR is operated by Leidos Biomedical Research, Inc., (formerly SAIC-Frederick, Inc.) for the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH).

FNLCR brings public and private partners together to address the most difficult cancer research challenges.

Scientific Impact

With our partners, we are developing faster and less expensive ways of turning laboratory discoveries into new diagnostic tests and treatments for cancer and AIDS.

Type of work ranges from basic research, translational research, technology development and research support, and clincial/pre-clinical development. Read about some of our success stories below.

View our Scientific Impact gallery.

Business Opps

Thank you for your interest in doing business with the Frederick National Laboratory for Cancer Research (FNLCR).

FNLCR is a Federally Funded Research and Development Center (FFRDC) operated by Leidos Biomedical Research under prime contract with the National Cancer Institute.

Extensive business opportunities exist for providing an array of vital goods and services in support of the operational, technical and research efforts required at the FFRDC.View our contracting opportunities.


The Frederick National Laboratory for Cancer Research and its prime contractor, Leidos Biomedical Research, Inc., are actively involved in nurturing the community in which their employees live and work. The campus supports a wide cross section of nonprofit organizations and charities. Frederick National Lab sponsors a series of educational programs from grade school through graduate school.

Read more about how we support our mission in the areas of business, health and more.

The RAS Initiative

The Frederick National Laboratory for Cancer Research (FNLCR) is an integral part of a coordinated research and development initiative created by the National Cancer Institute (NCI) to further scientific understanding of cancers driven by mutations in the RAS family of genes. Researchers have known for more than two decades that about one-third of all human cancers—including a high percentage of pancreatic, lung and colorectal cancers—are driven by mutations in RAS genes. Thus far, RAS-driven cancers have been virtually impossible to treat successfully and, in some cases, are actually aggravated by current targeted therapies.

The FNLCR is enlisting collaborators from all sectors of the global research community with the goal of developing an open interactive research model to understand how RAS mutant proteins function and to solve the challenges of treating RAS-dependent cancers. It is a high-risk undertaking that, if successful, could result in major dividends for human health. Read more about the RAS Initiative.

News & Multimedia